Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Allergan Plc (AGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 64,833,040
  • Shares Outstanding, K 339,440
  • Annual Sales, $ 15,941 M
  • Annual Income, $ -4,125,500 K
  • 36-Month Beta 1.19
  • Price/Sales 4.00
  • Price/Cash Flow 4.69
  • Price/Book 0.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 4.00
  • Number of Estimates 19
  • High Estimate 4.27
  • Low Estimate 3.80
  • Prior Year 4.15
  • Growth Rate Est. (year over year) -3.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
180.64 +4.57%
on 10/11/18
197.00 -4.12%
on 10/03/18
+2.82 (+1.52%)
since 09/18/18
3-Month
170.20 +10.98%
on 07/20/18
197.00 -4.12%
on 10/03/18
+13.03 (+7.41%)
since 07/18/18
52-Week
142.81 +32.27%
on 03/05/18
197.00 -4.12%
on 10/03/18
+1.74 (+0.93%)
since 10/18/17

Most Recent Stories

More News
What's in Store for Centene (CNC) This Earnings Season?

Centene's (CNC) third quarter should exhibit strong performances by its Government-backed and Medicaid businesses.

MOH : 142.40 (-0.51%)
AGN : 188.89 (-1.10%)
ANTM : 281.19 (+0.58%)
CNC : 145.90 (+0.37%)
EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq

EyePoint (EYPT) gains an FDA approval for its eye therapy Yutiq to help cure chronic non-infectious uveitis affecting the posterior segment of the eye.

ALIM : 0.98 (+1.56%)
AGN : 188.89 (-1.10%)
EYPT : 2.95 (-1.34%)
ABBV : 89.90 (-2.57%)
Can Allergan's Key Drugs, Solid Pipeline Abate Generic Woes?

Allergan (AGN) is facing loss of exclusivity for many blockbuster products. However, drugs like Botox/Linzess, new drugs and cost cuts can shield it from potential sales drop.

LLY : 113.31 (-0.25%)
AGN : 188.89 (-1.10%)
TEVA : 21.27 (+0.38%)
AMGN : 202.72 (-0.02%)
Allergan Announces Completion of Two Positive Safety Studies for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine

Allergan plc (NYSE: AGN) today announced the completion of two positive safety and tolerability studies of ubrogepant for the acute treatment of migraine. The first study (UBR-MD-04) evaluated the long-term...

AGN : 188.89 (-1.10%)
After Yesterday's Rally of 1.80% Shares Could Potentially Pullback

Allergan Plc (NYSE:AGN) traded in a range yesterday that spanned from a low of $183.40 to a high of $186.75. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $186.54...

AGN : 188.89 (-1.10%)
Advanced Dermatology and Cosmetic Surgery Expands Aesthetics Leadership Team, Jennifer Bancroft Joins as Vice President Aesthetics

Advanced Dermatology and Cosmetic Surgery, one of the nation's leaders in high quality dermatology, today announced the appointment of Jennifer Bancroft as Vice President of Aesthetics.

AGN : 188.89 (-1.10%)
FDA Approves Medicines360's sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years

Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, announced...

AGN : 188.89 (-1.10%)
Government Initiatives to Boost Global Atopic Dermatitis Market by 8.2% CAGR till 2023 – Asserts MRFR

VRX.TO : 30.80 (-3.33%)
ANAC : 99.06 (-0.14%)
AGN : 188.89 (-1.10%)
ALPMF : 16.8100 (-0.59%)
NVS : 86.24 (+1.13%)
REGN : 395.22 (-0.96%)
PFE : 44.00 (-1.28%)
BMY : 55.98 (-4.96%)
Invest Like Warren Buffett with These Stocks & ETF

Moat investing, popularized by Buffett, looks for attractively priced companies with sustainable competitive advantages.

MOAT : 45.42 (-1.11%)
AAPL : 216.02 (-2.34%)
CMP : 67.34 (-0.52%)
AGN : 188.89 (-1.10%)
AMZN : 1,770.72 (-3.33%)
PFE : 44.00 (-1.28%)
Aclaris Therapeutics to Acquire Worldwide Rights to RHOFADE(R) from Allergan

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet patient...

AGN : 188.89 (-1.10%)
ACRS : 12.17 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade AGN with:

Business Summary

Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan...

See More

Key Turning Points

2nd Resistance Point 193.59
1st Resistance Point 191.24
Last Price 188.89
1st Support Level 187.11
2nd Support Level 185.33

See More

52-Week High 197.00
Last Price 188.89
Fibonacci 61.8% 176.30
Fibonacci 50% 169.90
Fibonacci 38.2% 163.51
52-Week Low 142.81

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar